stockrow
Sunday 8 November 2026
Export IDXG’s income statement to Excel — free account
Interpace Biosciences, Inc.
IDXG
Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024.
- Revenue
- −1.09%
- EPS
- +104.1%
- Free cash flow
- −92.1%
Quarter to June 2026, against a year earlier
7.00
0.00
0.00%
Follow IDXG
Alert me
Interpace Biosciences, Inc. (IDXG) P/E ratio
As of 6 November 2026, Interpace Biosciences, Inc. (IDXG) trades at a P/E ratio of 0.3×. Over the past ten years it has ranged from 0.0× (December 2023) to 3.9× (March 2024); the current reading is higher than 64% of that period.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.2× | (88.34%) |
| FY2024 | 1.9× | (21.92%) |
| FY2023 | 2.4× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.3× | (16.10%) |
| Mar 2026 | 0.4× | 63.65% |
| Dec 2025 | 0.2× | (81.27%) |
| Sep 2025 | 1.2× | 47.09% |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.9×
Ten-year median
0.0×
Current reading's percentile
64
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IDXG Interpace Biosciences, Inc. | 0.3× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)